We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+5.71%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.65B
AUM Growth
-$277M
Cap. Flow
-$110M
Cap. Flow %
-4.17%
Top 10 Hldgs %
67.67%
Holding
75
New
11
Increased
7
Reduced
10
Closed
16

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$94.4M
2
SWTX
SpringWorks Therapeutics
SWTX
+$54.5M
3
QURE icon
uniQure
QURE
+$29.4M
4
ZYME icon
Zymeworks
ZYME
+$22.2M
5
XNCR icon
Xencor
XNCR
+$18.7M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$51.5M
2
VRDN icon
Viridian Therapeutics
VRDN
+$44.6M
3
NUVB icon
Nuvation Bio
NUVB
+$44M
4
PCVX icon
Vaxcyte
PCVX
+$40.3M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$33.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.51%
2 Miscellaneous 5.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$379M 14.35%
11,890,843
– –
ZYME icon
2
Zymeworks
ZYME
$2.02B
$220M 8.32%
15,028,079
+1,590,606
+12% +$22.2M
CRNX icon
3
Crinetics Pharmaceuticals
CRNX
$9B
$219M 8.29%
4,288,120
– –
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.9B
$210M 7.95%
1,706,469
– –
PRTA icon
5
Prothena Corp
PRTA
$479M
$160M 6.07%
11,584,280
– –
XNCR icon
6
Xencor
XNCR
$1.94B
$141M 5.34%
6,144,767
+814,351
+15% +$18.7M
PFE icon
7
CALL
Pfizer
PFE
$159B
$133M 5.02%
+5,000,000
New +$136M
ARVN icon
8
Arvinas
ARVN
$600M
$129M 4.88%
6,726,491
– –
ANAB icon
9
AnaptysBio
ANAB
$1.67B
$104M 3.94%
7,873,448
+78,452
+1% +$1.9M
SRPT icon
10
Sarepta Therapeutics
SRPT
$2.2B
$93.6M 3.54%
+770,000
New +$94.4M
JANX icon
11
Janux Therapeutics
JANX
$1.1B
$78.7M 2.98%
1,469,818
– –
QURE icon
12
uniQure
QURE
$3.38B
$60M 2.27%
+3,400,000
New +$29.4M
SWTX
13
DELISTED
SpringWorks Therapeutics
SWTX
$56.4M 2.13%
+1,560,000
New +$54.5M
CRSP icon
14
CRISPR Therapeutics
CRSP
$5.58B
$54.7M 2.07%
1,389,276
– –
IMNM icon
15
Immunome
IMNM
$3.13B
$41.2M 1.56%
3,879,415
– –
TECX
16
Tectonic Therapeutic
TECX
$696M
$39.2M 1.48%
849,143
– –
TNGX icon
17
Tango Therapeutics
TNGX
$3.94B
$32.8M 1.24%
10,630,736
-2,700,000
-20% -$12.5M
THRD
18
DELISTED
Third Harmonic Bio
THRD
$32.7M 1.24%
3,182,444
– –
KURA icon
19
Kura Oncology
KURA
$1.13B
$31M 1.17%
3,557,269
-2,249,602
-39% -$32.4M
NGNE icon
20
Neurogene
NGNE
$732M
$29.1M 1.1%
1,271,342
– –
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.37B
$27.6M 1.04%
3,418,068
– –
ETON icon
22
Eton Pharmaceutcials
ETON
$1.71B
$24.4M 0.92%
1,829,603
+1,263,528
+223% +$12.8M
MBX
23
MBX Biosciences
MBX
$3.03B
$23.2M 0.88%
1,259,273
+83,464
+7% +$1.78M
MDGL icon
24
Madrigal Pharmaceuticals
MDGL
$12.3B
$23.1M 0.87%
75,000
– –
VYGR icon
25
Voyager Therapeutics
VYGR
$218M
$22.2M 0.84%
3,917,546
– –
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2024 Portfolio in Review

As of Q4 2024, EcoR1 Capital held 75 positions worth $2.65B, down 9.5% from $2.92B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital withdrew a net $110M in Q4 2024, closing 16 positions and reducing 10 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $51.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Sarepta Therapeutics worth $93.6M.

  • EcoR1 Capital's largest Q4 2024 buy was Sarepta Therapeutics: 770,000 shares worth $93.6M.
  • EcoR1 Capital added most to Zymeworks in Q4 2024, an estimated $22.2M increase.
  • EcoR1 Capital's biggest Q4 2024 reduction was Kura Oncology, cutting an estimated $32.4M.
  • EcoR1 Capital fully exited Centessa Pharmaceuticals in Q4 2024, selling an estimated $51.5M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $2.65B portfolio in Q4 2024.
  • EcoR1 Capital opened 11 new positions and closed 16 in Q4 2024.
  • EcoR1 Capital's portfolio value fell 9.5% quarter-over-quarter to $2.65B.

Based on EcoR1 Capital's 13F filing for Q4 2024, filed 14 Feb 2025.